Department of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China; Postgraduate School, Bengbu Medical College, Bengbu, Anhui 233030, China.
Department of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China.
Parkinsonism Relat Disord. 2018 Oct;55:68-74. doi: 10.1016/j.parkreldis.2018.05.013. Epub 2018 May 16.
Metabolic syndrome (MetS) increases the risk of cognitive impairment in normal aging but this has not been studied in Parkinson's Disease (PD). The purpose of this study was to investigate the impact of MetS on cognitive impairment in PD.
This study investigated subjects older than 60 years who were diagnosed with PD. They were enrolled into this study between January 2010 and December 2011, and followed for 5 years. The assessment of cognitive function in subjects with PD was based on the cognitive and neuropsychiatric tests, and MetS was diagnosed according to the National Cholesterol Education Program's Adult Treatment Panel III. The subjects were divided into three groups according to the cognitive function at the end of follow-up: PD with normal cognitive function (PD-NC), mild cognitive impairment in PD (PD-MCI) and PD dementia (PDD).
Of the 787 subjects with PD included in our study, 255 (32.4%) were diagnosed with PD-MCI, and 105 (13.3%) were diagnosed with PDD. MetS was significantly associated with PD-MCI (odds radio [OR]: 1.45, 95% confidence interval [CI]: 1.17-1.72) and PDD (OR: 2.12, 95% CI: 1.57-2.83). The associations between MetS and the main cognition domains of PDD were statistically significant. The treatment of MetS was helpful in reducing the risk of PDD.
We found that MetS increase the risk of cognitive impairment in patients with PD, and is significantly associated with the severity of cognitive impairment. The results suggest that the intervention against MetS is helpful in managing cognitive impairment in PD.
代谢综合征（MetS）会增加正常衰老人群认知障碍的风险，但这在帕金森病（PD）中尚未得到研究。本研究的目的是探讨 MetS 对 PD 认知障碍的影响。
本研究调查了年龄在 60 岁以上被诊断为 PD 的患者。他们于 2010 年 1 月至 2011 年 12 月期间入组本研究，并随访 5 年。对 PD 患者的认知功能评估基于认知和神经心理测试，MetS 根据国家胆固醇教育计划成人治疗专家组 III 进行诊断。根据随访结束时的认知功能，将患者分为三组：PD 认知功能正常（PD-NC）、PD 轻度认知障碍（PD-MCI）和 PD 痴呆（PDD）。
在纳入本研究的 787 例 PD 患者中，255 例（32.4%）被诊断为 PD-MCI，105 例（13.3%）被诊断为 PDD。MetS 与 PD-MCI（优势比 [OR]：1.45，95%置信区间 [CI]：1.17-1.72）和 PDD（OR：2.12，95% CI：1.57-2.83）显著相关。MetS 与 PDD 的主要认知领域之间的关联具有统计学意义。MetS 的治疗有助于降低 PDD 的风险。
我们发现 MetS 增加了 PD 患者认知障碍的风险，并且与认知障碍的严重程度显著相关。结果表明，针对 MetS 的干预有助于管理 PD 患者的认知障碍。
